Skip to content

Alterola Biotech, Inc.: 10-Q filed 2013-09-06

What Alterola Biotech, Inc. reported in its quarterly report filed 2013-09-06 (fiscal Q3 2011): 16 published measures, 51 facts as tagged in accession 0001255294-13-000712.

This filing

Form
10-Q (quarterly report)
Filed
2013-09-06
Fiscal period
fiscal Q3 2011
Accession
0001255294-13-000712 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Alterola Biotech, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2011-06-306,700USD
At 2010-09-3028,228USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2011-06-30-89,250USD
At 2010-09-30-57,522USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2010-09-3028USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2010-10-01 to 2011-06-30-81,728USD273
2008-07-21 to 2011-06-30-340,368USD1075
2009-10-01 to 2010-06-30-62,702USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2010-10-01 to 2011-06-30-50,028USD273
2008-07-21 to 2011-06-30-277,418USD1075
2009-10-01 to 2010-06-30-60,199USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2010-10-01 to 2011-06-3050,000USD273
2008-07-21 to 2011-06-30288,618USD1075
2009-10-01 to 2010-06-3080,000USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2011-06-30-288,122USD
At 2010-09-30-206,394USD

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2011-06-30500USD
At 2010-09-30528USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2011-04-01 to 2011-06-30-2,400USD91
2010-10-01 to 2011-06-30-7,200USD273
2008-07-21 to 2011-06-30-9,290USD1075
2010-04-01 to 2010-06-30-60USD91
2009-10-01 to 2010-06-30-60USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2011-06-3095,950USD
At 2010-09-3085,750USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2011-04-01 to 2011-06-30-1,000USD91
2010-10-01 to 2011-06-30-74,528USD273
2008-07-21 to 2011-06-30-331,078USD1075
2010-04-01 to 2010-06-30-19,790USD91
2009-10-01 to 2010-06-30-62,462USD273

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2011-06-30120,892USD
At 2010-09-3056,142USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2011-04-01 to 2011-06-30-1,000USD91
2010-10-01 to 2011-06-30-74,528USD273
2008-07-21 to 2011-06-30-331,078USD1075
2010-04-01 to 2010-06-30-19,790USD91
2009-10-01 to 2010-06-30-62,462USD273

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2011-04-01 to 2011-06-30-3,400USD91
2010-10-01 to 2011-06-30-81,728USD273
2008-07-21 to 2011-06-30-340,368USD1075
2010-04-01 to 2010-06-30-19,850USD91
2009-10-01 to 2010-06-30-62,702USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2011-04-01 to 2011-06-301,000USD91
2010-10-01 to 2011-06-303,028USD273
2008-07-21 to 2011-06-30179,571USD1075
2010-04-01 to 2010-06-3019,790USD91
2009-10-01 to 2010-06-3058,642USD273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2011-04-01 to 2011-06-30-2,400USD91
2010-10-01 to 2011-06-30-7,200USD273
2008-07-21 to 2011-06-30-9,290USD1075
2010-04-01 to 2010-06-30-60USD91

Inspect the source

Entity
Alterola Biotech, Inc. / CIK 0001442999
Captured
SEC response SHA-256
87a3a16f9156f52960516ff7604a147caa80abebfe964591df0bd913491df844

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001442999.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))